Tag: letrozoleFemara

Letrozole: An aromatase inhibitor used to treat ER+ breast cancer. Aromatase inhibitors are designed to inhibit the action of the enzyme aromatase, which converts androgens into estrogens within the body. Letrozole is the generic version of Femara.

Articles

News

07/19/12: Aromatase inhibitors are less effective in women with high BMI
09/07/11: Strongly ER+ lobular breast cancer responds well to letrozole
07/17/11: Increasing aromatase inhibitor side effects make tamoxifen attractive

Studies

Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial Cite
Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, et al. Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial. International Journal of Cancer. Wiley; 2025; 10.1002/ijc.70037
Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBas) Cite
Yuste MT, Sainz‐Gil M, Escudero E, Marín P. Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBas). Pharmacology Research & Perspectives. Wiley; 2025; 13 10.1002/prp2.70075
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial Cite
Faltinová M, Vehmanen L, Lyytinen H, Savolainen-Peltonen H, Virtanen A, Haanpää M, et al. Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07564-8
Comparative study between effect of both drugs Tamoxifen versus Letrozole on endometrial thickness as Hormonal adjuvant therapy in breast cancer Cite
Alsaadi KAJS, Zakria AM, Saeed AMM, Mohamed MS, Ghoneim WAW, Selim MM, et al. Comparative study between effect of both drugs Tamoxifen versus Letrozole on endometrial thickness as Hormonal adjuvant therapy in breast cancer. International journal of health sciences. Universidad Tecnica de Manabi; 2022;:11163-11175 10.53730/ijhs.v6ns6.13067
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole. Cite
Abdel Gelil M. Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2023; 9:8-8 10.1200/go.2023.9.supplement_1.8
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement Cite
Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07054-3
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment Cite
Bezerra PHA, Amaral C, Almeida CF, Correia-da-Silva G, Torqueti MR, Teixeira N. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. Molecules. MDPI AG; 2023; 28:4893 10.3390/molecules28134893
Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer Cite
Bergman R, Berko YA, Sanchez V, Sanders ME, Gonzalez-Ericsson PI, Arteaga CL, et al. Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06794-y
Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model Cite
Hilakivi-Clarke L, Da Silva JL, Blaes A, Hoeppner L. Abstract P5-18-12: Cardioprotective effects of walnuts against aromatase inhibitor: Pilot study in a zebrafish model. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P5-18-12-P5-18-12 10.1158/1538-7445.sabcs21-p5-18-12
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Cite
Bradley R, Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. Elsevier BV; 2022; 10.1016/s1470-2045(21)00758-0
Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation Cite
Heo JH, Lee SR, Jo SL, Yang H, Lee HW, Hong E. Letrozole Accelerates Metabolic Remodeling through Activation of Glycolysis in Cardiomyocytes: A Role beyond Hormone Regulation. International Journal of Molecular Sciences. MDPI AG; 2022; 23:547 10.3390/ijms23010547
Impact of Nigella Sativa on body weight, volume and weight of ovary in Letrozole Induced POS in Mice Cite
Anwar N, Nadeem A, Naheed K, Arshad Jarral S, Saad Abdullah M, Asad A, et al. Impact of Nigella Sativa on body weight, volume and weight of ovary in Letrozole Induced POS in Mice. Pakistan Journal of Medical and Health Sciences. Lahore Medical and Dental College; 2021; 15:2355-2357 10.53350/pjmhs211592355
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions Cite
Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, et al. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients. MDPI AG; 2021; 13:3730 10.3390/nu13113730
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy Cite
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, et al. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Annals of Oncology. Elsevier BV; 2021; 32:1256-1266 10.1016/j.annonc.2021.07.017
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial Cite
Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2021; 10.1016/s1470-2045(21)00352-1
Anticancer effect of the letrozole-quercetin combination mediated by FOXOs and estrogen receptors in breast cancer cells Cite
ÇİLESİZ Y, ÇEVİK Ö. Anticancer effect of the letrozole-quercetin combination mediated by FOXOs and estrogen receptors in breast cancer cells. Journal of Research in Pharmacy. Marmara University; 2021; 25(4):479-489 10.29228/jrp.38
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial Cite
Faltinová M, Vehmanen L, Lyytinen H, Haanpää M, Hämäläinen E, Tiitinen A, et al. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06168-w
Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells Cite
Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. Elsevier BV; 2020; 10.1016/j.jtumed.2020.10.017
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial Cite
Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2020; 21:1443-1454 10.1016/s1470-2045(20)30458-7
Abstract 1441: Aspirin in combination with Letrozole or Olaparib induced apoptosis in estrogen receptor-positive T-47D & triple negative MDA-MB-231 breast cancer cell lines Cite
Kamel MESE, Sheweita SA, Sultan AS. Abstract 1441: Aspirin in combination with Letrozole or Olaparib induced apoptosis in estrogen receptor-positive T-47D & triple negative MDA-MB-231 breast cancer cell lines. Immunology. American Association for Cancer Research; 2020; 10.1158/1538-7445.am2020-1441
Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study Cite
Elliott MJ, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, et al. Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-0166-y
The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer Cite
VOGEL C, MALTER W, MORGENSTERN B, LUDWIG S, VEHRESCHILD JJ, HAMACHER S, et al. The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2019; 39:2647-2659 10.21873/anticanres.13389
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial Cite
Mamounas EP, Bandos H, Lembersky BC, Jeong J, Geyer CE, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. Elsevier BV; 2019; 20:88-99 10.1016/s1470-2045(18)30621-1
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial Cite
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, et al. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:105-114 10.1200/jco.18.00440
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer Cite
Li L, Chang B, Jiang X, Fan X, Li Y, Li T, et al. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4878-4
Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy Cite
Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, et al. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology. Elsevier BV; 2018; 25:291-300.e3 10.1016/j.chembiol.2017.12.010
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Cite
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Elsevier BV; 2018; 19:127-138 10.1016/s1470-2045(17)30715-5
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) Cite
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 110:40-48 10.1093/jnci/djx134
Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line Cite
Rahideh ST, Keramatipour M, Nourbakhsh M, Koohdani F, Hoseini M, Talebi S, et al. Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line. Biochemistry and Cell Biology. Canadian Science Publishing; 2017; 95:468-473 10.1139/bcb-2016-0206
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Cite
Shapiro AC, Adlis SA, Robien K, Kirstein MN, Liang S, Richter SA, et al. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:501-512 10.1007/s10549-016-3710-6
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence Cite
Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, et al. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2452-2459 10.1200/jco.2015.63.8619
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Cite
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. Massachusetts Medical Society; 2016; 375:209-219 10.1056/nejmoa1604700
Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole Cite
Arul Vijaya Vani S, Ananthanarayanan P, Kadambari D, Harichandrakumar K, Niranjjan R, Nandeesha H. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole. Clinica Chimica Acta. Elsevier BV; 2016; 459:53-56 10.1016/j.cca.2016.05.020
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells Cite
Wang W, Belosay A, Yang X, Hartman JA, Song H, Iwaniec UT, et al. Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2016; 33:475-485 10.1007/s10585-016-9792-z
MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer Cite
Isanejad A, Alizadeh AM, Amani Shalamzari S, Khodayari H, Khodayari S, Khori V, et al. MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer. Life Sciences. Elsevier BV; 2016; 151:30-40 10.1016/j.lfs.2016.02.090
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Cite
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:2772-2779 10.1200/jco.2015.60.8133
A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors Cite
Schech A, Yu S, Goloubeva O, McLenithan J, Sabnis G. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors. Endocrine-Related Cancer. Bioscientifica; 2015; 22:645-656 10.1530/erc-15-0168
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Cite
HOLE S, PEDERSEN AM, HANSEN SK, LUNDQVIST J, YDE CW, LYKKESFELDT AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. International Journal of Oncology. Spandidos Publications; 2015; 46:1481-1490 10.3892/ijo.2015.2850
Coadministrating Luteolin Minimizes the Side Effects of the Aromatase Inhibitor Letrozole Cite
Li F, Wong TY, Lin S, Chow S, Cheung W, Chan FL, et al. Coadministrating Luteolin Minimizes the Side Effects of the Aromatase Inhibitor Letrozole. The Journal of Pharmacology and Experimental Therapeutics. Elsevier BV; 2014; 351:270-277 10.1124/jpet.114.216754
Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells Cite
Ismail AM, In LL, Tasyriq M, Syamsir DR, Awang K, Omer Mustafa AH, et al. Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells. Food and Chemical Toxicology. Elsevier BV; 2013; 62:817-824 10.1016/j.fct.2013.10.024
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Cite
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:1036-1042 10.1093/jnci/djt146
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Cite
Wasan K, Goss P, Pritchard P, Shepherd L, Palmer M, Liu S, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology. Elsevier BV; 2005; 16:707-715 10.1093/annonc/mdi158
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study Cite
Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 136:769-776 10.1007/s10549-012-2294-z
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer Cite
Li F, Chow S, Cheung W, Chan FL, Chen S, Leung LK. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer. The Journal of Nutritional Biochemistry. Elsevier BV; 2013; 24:1112-1116 10.1016/j.jnutbio.2012.08.010
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results Cite
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology. Elsevier BV; 2013; 24:398-405 10.1093/annonc/mds277
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Cite
Goss P, Ingle J, Martino S, Robert N, Muss H, Livingston R, et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. Elsevier BV; 2013; 24:355-361 10.1093/annonc/mds330
Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer Cite
Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M. Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:2977-2980 10.1200/jco.2012.42.0273
Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy Cite
Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. British Journal of Cancer. Springer Science and Business Media LLC; 2011; 105:1825-1829 10.1038/bjc.2011.470
Final 5-year results of Z-FAST trial Cite
Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of Z-FAST trial. Cancer. Wiley; 2011; 118:1192-1201 10.1002/cncr.26313
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Cite
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. Elsevier BV; 2012; 23:1474-1481 10.1093/annonc/mdr448
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy Cite
Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 130:871-877 10.1007/s10549-011-1735-4
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Cite
Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1299-1309 10.1093/jnci/djr242
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Cite
Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 120:127-134 10.1007/s10549-009-0692-7
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Cite
Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. Oxford University Press (OUP); 2008; 29:2162-2168 10.1093/carcin/bgn161
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer Cite
Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:111-118 10.1007/s10549-009-0495-x